These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24318973)

  • 1. Clinical significance of S100A2 expression in gastric cancer.
    Liu YF; Liu QQ; Wang X; Luo CH
    Tumour Biol; 2014 Apr; 35(4):3731-41. PubMed ID: 24318973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of S100A2 expression by TGF-β-induced MEK/ERK signalling and its role in cell migration/invasion.
    Naz S; Ranganathan P; Bodapati P; Shastry AH; Mishra LN; Kondaiah P
    Biochem J; 2012 Oct; 447(1):81-91. PubMed ID: 22747445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of altered S100A2 expression in gastric cancer.
    Zhao Y; Zhang TB; Wang Q
    Oncol Rep; 2013 Apr; 29(4):1556-62. PubMed ID: 23337980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.
    Zhang Q; Xia T; Qi C; Du J; Ye C
    BMC Cancer; 2022 Jan; 22(1):77. PubMed ID: 35042454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and clinical significance of S100A2 and p63 in esophageal carcinoma.
    Cao LY; Yin Y; Li H; Jiang Y; Zhang HF
    World J Gastroenterol; 2009 Sep; 15(33):4183-8. PubMed ID: 19725154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S100A2 protein and non-small cell lung cancer. The dual role concept.
    Hountis P; Matthaios D; Froudarakis M; Bouros D; Kakolyris S
    Tumour Biol; 2014 Aug; 35(8):7327-33. PubMed ID: 24863947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100A2 induces metastasis in non-small cell lung cancer.
    Bulk E; Sargin B; Krug U; Hascher A; Jun Y; Knop M; Kerkhoff C; Gerke V; Liersch R; Mesters RM; Hotfilder M; Marra A; Koschmieder S; Dugas M; Berdel WE; Serve H; Müller-Tidow C
    Clin Cancer Res; 2009 Jan; 15(1):22-9. PubMed ID: 19118029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis.
    Ohuchida K; Mizumoto K; Miyasaka Y; Yu J; Cui L; Yamaguchi H; Toma H; Takahata S; Sato N; Nagai E; Yamaguchi K; Tsuneyoshi M; Tanaka M
    J Pathol; 2007 Nov; 213(3):275-82. PubMed ID: 17940995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma.
    Luo J; Zhu Y; Yang G; Gong L; Wang B; Liu H
    Diagn Cytopathol; 2011 Oct; 39(10):752-7. PubMed ID: 20949468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A2, a potential marker for early recurrence in early-stage oral cancer.
    Tsai ST; Jin YT; Tsai WC; Wang ST; Lin YC; Chang MT; Wu LW
    Oral Oncol; 2005 Apr; 41(4):349-57. PubMed ID: 15792606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma.
    Tsai WC; Tsai ST; Jin YT; Wu LW
    Mol Cancer Res; 2006 Aug; 4(8):539-47. PubMed ID: 16908593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic significance of S100A2 protein in squamous cell carcinoma of the esophagus.
    Kyriazanos ID; Tachibana M; Dhar DK; Shibakita M; Ono T; Kohno H; Nagasue N
    Oncol Rep; 2002; 9(3):503-10. PubMed ID: 11956617
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Liu LP; Sheng XP; Shuai TK; Zhao YX; Li B; Li YM
    World J Gastroenterol; 2018 Oct; 24(40):4565-4577. PubMed ID: 30386106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.
    Bachet JB; Maréchal R; Demetter P; Bonnetain F; Cros J; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
    Eur J Cancer; 2013 Aug; 49(12):2643-53. PubMed ID: 23726265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulated Wnt1-inducible signaling pathway protein 1 correlates with poor prognosis and drug resistance by reducing DNA repair in gastric cancer.
    Zhang LH; Wang Y; Fan QQ; Liu YK; Li LH; Qi XW; Mao Y; Hua D
    World J Gastroenterol; 2019 Oct; 25(38):5814-5825. PubMed ID: 31636474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes.
    Matsubara D; Niki T; Ishikawa S; Goto A; Ohara E; Yokomizo T; Heizmann CW; Aburatani H; Moriyama S; Moriyama H; Nishimura Y; Funata N; Fukayama M
    Cancer Sci; 2005 Dec; 96(12):844-57. PubMed ID: 16367903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and prognostic significance of C/EBP homologous protein (CHOP) in advanced gastric cancer.
    Zhang X; Zhou T; Li W; Zhang T; Che N; Zu G
    Pathol Res Pract; 2018 Aug; 214(8):1105-1109. PubMed ID: 29910063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFIC1 inhibits the migration and invasion of MDA-MB-231 cells through S100A2-mediated inactivation of MEK/ERK pathway.
    Zhang J; Wang Z; Liang Z; Jin C; Shi Y; Fan M; Hu X; Wan Y
    Arch Biochem Biophys; 2023 Jan; 734():109497. PubMed ID: 36574914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration.
    Nagy N; Brenner C; Markadieu N; Chaboteaux C; Camby I; Schäfer BW; Pochet R; Heizmann CW; Salmon I; Kiss R; Decaestecker C
    Lab Invest; 2001 Apr; 81(4):599-612. PubMed ID: 11304580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of S100A2 inhibits the aggressiveness of endometrial cancer by activating STING pathway.
    Li C; Zhu D; Cao X; Li Y; Hao X
    J Obstet Gynaecol; 2024 Dec; 44(1):2361849. PubMed ID: 38920019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.